Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment-Reference-Cited by-同舟云学术

Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment

Published:2020-09-19 Issue:1 Volume:185 Page:85-94
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Deng Jiehui,Thennavan Aatish,Shah Suhagi,Bagdatlioglu Ece,Klar Natalie,Heguy Adriana,Marier Christian,Meyn Peter,Zhang Yutong,Labbe Kristen,Almonte Christina,Krogsgaard Michelle,Perou Charles M.,Wong Kwok-Kin^ORCID,Adams Sylvia

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-020-05936-4.pdf

Reference33 articles.

1. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34(21):2460–2467. https://doi.org/10.1200/JCO.2015.64.8931

2. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fasso M, Molinero L, Schmid P (2019) Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 5(1):74–82. https://doi.org/10.1001/jamaoncol.2018.4224

3. Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortes J (2018) Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase 2 KEYNOTE-086 study. Ann Oncol. https://doi.org/10.1093/annonc/mdy517

4. Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P (2018) Title: pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase 2 KEYNOTE-086 study. Ann Oncol. https://doi.org/10.1093/annonc/mdy518

5. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, Investigators IMT (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108–2121. https://doi.org/10.1056/NEJMoa1809615

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-Cell RNA-Sequencing: Opening New Horizons for Breast Cancer Research;International Journal of Molecular Sciences;2024-08-31

2. Pertpy: an end-to-end framework for perturbation analysis;2024-08-07

3. MAT as a promising therapeutic strategy against triple-negative breast cancer via inhibiting PI3K/AKT pathway;Scientific Reports;2023-07-31

4. Targeting molecular cross-talk between tumor cells and tumor associated macrophage as therapeutic strategy in triple negative breast cancer;International Immunopharmacology;2023-06

5. Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy;Frontiers in Oncology;2023-05-22